Letters To The Editor
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. May 8, 2016; 8(13): 605-606
Published online May 8, 2016. doi: 10.4254/wjh.v8.i13.605
Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after surgery: A comment for moving forward
Jian-Hong Zhong, Tian Yang, Bang-De Xiang, Le-Qun Li, Liang Ma
Jian-Hong Zhong, Bang-De Xiang, Le-Qun Li, Liang Ma, Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Tian Yang, Department of Hepatobiliary Surgery, Eastern Hepa-tobiliary Surgery Hospital, Second Military Medical University, Shanghai 201800, China
Author contributions: Zhong JH, Yang T and Xiang BD contributed equally to this work; Zhong JH designed the study and wrote the manuscript; Zhong JH, Yang T, Xiang BD, Li LQ and Ma L analyzed the data; all authors reviewed the manuscript.
Supported by The Guangxi University of Science and Tech-nology Research Projects, No. KY2015LX056; the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Zhuang Autonomous Region, No. Z2015621, and No. Z2014241; the Innovation Project of Guangxi Graduate Education, No. YCBZ2015030; and the Guangxi Science and Technology Development Projects, No. 14124003-4.
Conflict-of-interest statement: The authors declare no conflicts of interest regarding this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Liang Ma, MD, Department of Hepato-biliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, He Di Rd #71, Nanning 530021, Guangxi Zhuang Autonomous Region, China. xitongpingjia@163.com
Telephone: +86-771-5330855 Fax: +86-771-5312000
Received: February 18, 2016
Peer-review started: February 19, 2016
First decision: March 1, 2016
Revised: March 4, 2016
Accepted: March 22, 2016
Article in press: March 23, 2016
Published online: May 8, 2016
Processing time: 76 Days and 0.8 Hours
Abstract

Recurrence rate of hepatocellular carcinoma remains quite high even after surgery, and no postoperative therapies have been definitively shown to prevent hepatocellular carcinoma recurrence. A previous study showed that therapy with nucleos(t)ide analogues given to such patients after surgery significantly improved survival. However, many questions still exist about the usage of nucleos(t)ide analogues for patients with hepatocellular carcinoma after surgery.

Keywords: Antiviral therapy; Hepatocellular carcinoma; Hepatitis B virus; Unanswered question

Core tip: Some important points about the usage of nucleos(t)ide analogues for patients with hepatocellular carcinoma after surgery in clinic were pointed out.